The treatment of diabetes with new generation drugs

Autor: Katarzyna Borkowska, Szymon Jan Marosz, Paulina Mikulska, Aleksnadra Joanna Borkowska, Jolanta Kowieska
Rok vydání: 2020
Předmět:
Zdroj: Journal of Education, Health and Sport, Vol 10, Iss 9, Pp 690-696 (2020)
ISSN: 2391-8306
DOI: 10.12775/jehs.2020.10.09.083
Popis: MaroszSzymon, BorkowskaAleksandra, MikulskaPaulina,BorkowskaKatarzyna, Kowieska Jolanta. The treatment of diabetes with new generation drugs. Journal of Education, Health and Sport.2020;10(9):690-696. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2020.10.09.083 https://apcz.umk.pl/czasopisma/index.php/JEHS/article/view/JEHS.2020.10.09.083 https://zenodo.org/record/4048524 The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019. © The Authors 2020; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 10.09.2020. Revised: 24.09.2020. Accepted: 24.09.2020. The treatment of diabetes with new generation drugs Szymon Marosz1,Aleksandra Borkowska1, Paulina Mikulska2, Katarzyna Borkowska2, Jolanta Kowieska2 1Chair and Department of Epidemiology and Clinical Research Methodology, Medical University of Lublin 2Mazovian Regional Hospital of St. John Paul II in Siedlce Sp. z o.o. Corresponding author: Aleksandra Borkowska: borkowska.ola231@gmail.com ORICID ID: Szymon Marosz: https://orcid.org/0000-0003-4774-8449 Aleksandra Borkowska: https://orcid.org/0000-0002-0950-2176 Katarzyna Borkowska: https://orcid.org/0000-0002-2090-7887 Paulina Mikulska: https://orcid.org/0000-0003-0876-6150 Jolanta Kowieska: https://orcid.org/0000-0001-5257-686X Abstract Introduction:Diabetes is a global problem, affecting nearly 422 million people around the world. Pathogenesis includes a defect in secretion or insulin activity. This results in an increase in the glucose level, which is associated with the development of complications. These include changes in peripheral vessels and nerves that lead to their damage. It is necessary to introduce appropriate treatment in the earliest stages of the disease to prevent these effects. Materials and methods:The aim of this work is to present knowledge about the treatment based on the recommendations of the Polish Diabetes Association, American Diabetes Association, as well as a literature review and analysis of publications published on PubMed and Google Scholar platforms. Results:Over the years, the recommendations and recommendations for treatment change. Recently, a greater role has been given to the latest antidiabetic drugs. This group includes SGLT-2 inhibitors as well as incremental drugs, the main representatives of which are GLP-1 analogues. These drugs affect the level of glycemia, but also have a beneficial effect on weight reduction and reduce the risk of cardiovascular events. Recently, Poland has introduced reimbursement of some new generation antidiabetic drugs such as dapaglyphosin, empaglyphosin and canaglyphosin. Conclusions:Dynamic development of diabetes treatment helps to slow down the course of the disease and postpones the introduction of insulin therapy as the final treatment method. Reimbursement of some antidiabetic drugs enables patients to have better access to drugs that have not been within their reach so far. The changes introduced are, in a way, groundbreaking in the treatment of diabetes. Key words: diabetes, GLP-1 analogues, SGLT-2 inhibitors.
Databáze: OpenAIRE
Externí odkaz: